Keryx Biopharmaceuticals (NASDAQ:KERX) reported second-quarter financial results yesterday and provided an update on its ongoing US launch of its dialysis drug, Auryxia. The Boston-based …
Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced its financial results …
Keryx Biopharmaceuticals (NASDAQ:KERX) announced the appointment of Scott A. Holmes to Chief Financial Officer effective immediately.
Health care analysts are weighing in today on the drug maker Keryx Biopharmaceuticals (NASDAQ:KERX), following the news that the Committee for Medicinal Products for Human Use in …
Keryx Biopharmaceuticals (NASDAQ:KERX) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion …
In a research report issued on today, Cowen analyst Boris Peaker downgraded shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from an Outperfrom to a Market Perform …
Keryx Biopharmaceuticals (NASDAQ:KERX) shares fell more than -5% in pre-market trading down to $9.06 after Boris Peaker at Cowen & Co.
On Wednesday, Keryx Biopharmaceuticals (NASDAQ:KERX) made the announcement that two major insurance providers added Auryxia, a drug used to control serum phosphorous levels in patients with …
Maxim Group analyst Jason Kolbert weighed in today with a few insights on Keryx Biopharmaceuticals (NASDAQ:KERX) after the company announced that two national insurance providers have added …
Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, announced that two national insurance providers …